Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAb52-29.1-ADC
- Development stage
- Preclinical
- Lead developer
- MedAbome
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal
01
Overview
MAb52-29.1-ADC is a first-in-class antibody-drug conjugate (ADC) targeting Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166), a glycoprotein overexpressed in various solid and hematologic malignancies. Developed by MedAbome, Inc., the ADC consists of a monoclonal antibody (MAb52-29.1) that recognizes a tumor-restricted conformational epitope of ALCAM, conjugated to the microtubule inhibitor monomethyl auristatin E (MMAE) via a protease-cleavable MC-Vc-PAB linker with a drug-to-antibody ratio (DAR) of 4. The antibody component exhibits high binding affinity and efficient internalization. In preclinical studies, MAb52-29.1-ADC demonstrated potent anti-tumor efficacy in xenograft models of triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and gastric cancer, with a favorable safety profile in preliminary toxicology assessments.
- Other names
- anti-ALCAM ADC
02
Targets
TUBB (Tubulin (alpha and beta subunits))ALCAM (Activated leukocyte cell adhesion molecule)
Beyond the preview
Go deeper on MAb52-29.1-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAb52-29.1-ADC.